Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019.
J Chin Med Assoc
; 83(9): 817-821, 2020 09.
Article
in English
| MEDLINE | ID: covidwho-611348
ABSTRACT
As the coronavirus disease 2019 (COVID-19, also called severe acute respiratory syndrome coronavirus-2) outbreak accelerates, vigorous and diverse efforts were made in developing treatment strategies. In addition to direct acting agents, increasing evidence showed some potential adjuvant therapies with promising efficacy against COVID-19. These therapies include immunomodulators (i.e. intravenous immunoglobulin, thymosin α-1, interleukin [IL]-6, tocilizumab, cyclosporine, thalidomide, fingolimod), Chinese medicines (i.e. glycyrrhizin, baicalin, Xuebijing), anti-vascular endothelial growth factors (bevacizumab), estrogen modulating drugs, statins, and nutritional supplements (i.e. vitamins A, B, C, D, E and zinc). This article reviewed the pharmacological development of potential adjuvants for COVID-19 treatment.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Betacoronavirus
Topics:
Traditional medicine
Limits:
Humans
Language:
English
Journal:
J Chin Med Assoc
Journal subject:
Medicine
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS